Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Should You Buy?

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $109.10 and last traded at $108.64, with a volume of 2089980 shares traded. The stock had previously closed at $108.17.

Analyst Ratings Changes

Several analysts recently weighed in on HALO shares. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Citizens Jmp upped their price target on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Stock Up 0.6%

The firm has a market cap of $12.41 billion, a price-to-earnings ratio of 32.63, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85. The stock has a 50-day moving average of $84.73 and a 200-day moving average of $74.19. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the company earned $1.54 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 64,103 shares of company stock worth $5,226,496. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HALO. MidFirst Bank acquired a new position in Halozyme Therapeutics in the second quarter worth approximately $27,000. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth $28,000. Measured Wealth Private Client Group LLC grew its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $30,000. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.